Takeda (TAK) Enters Pact with Ovid Therapeutics (OVID) for Rights to Develop and Commercialize Soticlestat for Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome

Go back to Takeda (TAK) Enters Pact with Ovid Therapeutics (OVID) for Rights to Develop and Commercialize Soticlestat for Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome
(NASDAQ: OVID) Delayed: 3.24 -0.26 (7.43%)
Previous Close $3.50    52 Week High
Open $3.53    52 Week Low
Day High $3.53    P/E N/A 
Day Low $3.23    EPS
Volume 447,577       

(NYSE: TAK) Delayed: 16.85 +0.01 (0.06%)
Previous Close $16.84    52 Week High $0.55 
Open $16.80    52 Week Low $0.55 
Day High $16.90    P/E N/A 
Day Low $16.78    EPS $-0.20 
Volume 1,811,136